GSK in talks to buy cancer biotech Nuvalent for more than $9bn



A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year



Source link

You may be interested

Leave a Reply

Your email address will not be published. Required fields are marked *